These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32312520)

  • 1. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
    Cai J; Chen J; Wu T; Cheng Z; Tian Y; Pu C; Shi W; Suo X; Wu X; Zhang K
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1170-1176. PubMed ID: 32312520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
    Sun W; He B; Yang B; Hu W; Cheng S; Xiao H; Yang Z; Wen X; Zhou L; Xie H; Shen X; Wu J; Zheng S
    Lab Invest; 2018 Jun; 98(6):734-744. PubMed ID: 29467456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.
    Chan YT; Wu J; Lu Y; Li Q; Feng Z; Xu L; Yuan H; Xing T; Zhang C; Tan HY; Feng Y; Wang N
    Mol Cancer; 2024 Apr; 23(1):74. PubMed ID: 38582885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Establishment and gene expression analysis of drug-resistant cell lines in hepatocellular carcinoma induced by sorafenib].
    Ma B; Tian ZH; Qu L; Liu YX; Zhang H; Ding HR
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):207-213. PubMed ID: 32306000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.
    Li L; Yu S; Hu Q; Hai Y; Li Y
    Int J Biol Sci; 2021; 17(12):3133-3144. PubMed ID: 34421355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells.
    Chu H; Wu C; Zhao Q; Sun R; Yang K; Zhao B; Liu Y; Liang Z; Zhong S; Zhang L; Zhang Y
    Carcinogenesis; 2021 May; 42(5):753-761. PubMed ID: 33677528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
    Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.
    Kong H; Sun J; Zhang W; Zhang H; Li H
    Bioengineered; 2022 Feb; 13(2):3108-3121. PubMed ID: 35037556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
    Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
    Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
    Zhang Z; He CZ; Qin YQ; Liao JJ; Huang ST; Mo S; Li HM; Lin JY
    Aging (Albany NY); 2020 Nov; 12(23):24255-24269. PubMed ID: 33234725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma.
    Pang L; Xu L; Yuan C; Li X; Zhang X; Wang W; Guo X; Ouyang Y; Qiao L; Wang Z; Liu K
    Mol Carcinog; 2019 Nov; 58(11):2118-2126. PubMed ID: 31465134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
    Wei L; Lee D; Law CT; Zhang MS; Shen J; Chin DW; Zhang A; Tsang FH; Wong CL; Ng IO; Wong CC; Wong CM
    Nat Commun; 2019 Oct; 10(1):4681. PubMed ID: 31615983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Miyazaki K; Okikawa S; Takasu C; Shimada M
    Cancer Sci; 2021 Sep; 112(9):3545-3554. PubMed ID: 34159680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.
    Tang W; Chen Z; Zhang W; Cheng Y; Zhang B; Wu F; Wang Q; Wang S; Rong D; Reiter FP; De Toni EN; Wang X
    Signal Transduct Target Ther; 2020 Jun; 5(1):87. PubMed ID: 32532960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.